Sfoglia per Autore  

Opzioni
Mostrati risultati da 21 a 40 di 115
Titolo Tipologia Data di pubblicazione Autori File
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic 01 - Articolo su rivista 2022 Russo, SelenaBani, MarcoTerraneo, MarcoNuvolati, GiampaoloCazzaniga, Marina ElenaStrepparava, Maria Grazia +
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 01 - Articolo su rivista 2021 Vanoni, MarcoBonfanti, PaoloCazzaniga, Marina ElenaMessa, CristinaAlberghina, Lilia +
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 01 - Articolo su rivista 2021 Bidoli P.Romiti A.Bidoli P.Cazzaniga M.Pasquini E.Pavesi L. +
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study 01 - Articolo su rivista 2021 Cazzaniga M. E. +
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 01 - Articolo su rivista 2021 Bani, MarcoRossi, EmanuelaCortinovis, DiegoRusso, SelenaCicchiello, FedericaCazzaniga, Marina ElenaBidoli, PaoloValsecchi, Maria GraziaStrepparava, Maria Grazia +
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study 01 - Articolo su rivista 2021 Galimberti, StefaniaLeone, Biagio EugenioPacifico, ClaudiaCicchiello, FedericaCazzaniga, Marina Elena +
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 99 - Altro 2021 Bonfanti P.Squillace N.Biondi A.Cazzaniga M. +
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) 01 - Articolo su rivista 2021 Cazzaniga ME +
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 01 - Articolo su rivista 2021 Galimberti S.Valsecchi M. G.Squillace N.Cazzaniga M. E.Bonfanti P. +
Mapping the human genetic architecture of COVID-19 01 - Articolo su rivista 2021 Invernizzi, PietroGerussi, AlessioBiondi, AndreaFoti, GiuseppeValsecchi, Maria G.D’Angiò, MariellaCazzaniga, MarinaFaverio, PaolaBonfanti, PaoloCrotti, Lia +
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial 01 - Articolo su rivista 2021 Cazzaniga M. +
Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project 01 - Articolo su rivista 2021 Cazzaniga M. E. +
Metronomic chemotherapy 01 - Articolo su rivista 2021 Cazzaniga M. E.Cordani N.Cerrito M. G. +
A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring 02 - Intervento a convegno 2020 Alberti, PCicchiello, FCavaletti, GCazzaniga, ME +
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 01 - Articolo su rivista 2020 Biondi A.Bettini L. R.Bonfanti P.Foti G.Bellani G.Citerio G.Pesci A.Valsecchi M. G.Cazzaniga M. +
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: A multi-cycle, phase II study 01 - Articolo su rivista 2020 Cazzaniga M. E.Giordano M. +
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 01 - Articolo su rivista 2020 Cazzaniga M. E.Bidoli P. +
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study 01 - Articolo su rivista 2020 Cazzaniga M. +
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 01 - Articolo su rivista 2020 Cazzaniga M. +
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 01 - Articolo su rivista 2020 Cazzaniga M. E.Zambelli A. +
Mostrati risultati da 21 a 40 di 115
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile